It does seem that what has changed is a major focus on modifying...

It does seem that what has changed is a major focus on modifying the libraries to contain peptides specifically for cell penetration, from less than 40% cell penetrating to over 90%. I assume that is 90% of billions?? And then scanning those libraries at far higher rates.

Only frustration is i thought we did or could already do those things. I guess that is the result of the much more scientifically informative updates they have given lately. Im hoping if i can understand all this and even why cre is exciting then hopefully others can too. Imagine having fpp that only enters heart cells or kidney or etc after systemic delivery?? If only we could find a fpp that only hits tumor cells even the simplest test would be to couple tjat with some sort of chemo drug?? Or am i jumpong too far. I guess tyhat was the intention of imyc to some degree but they eent from tumors to blood cancer to stopping that line of research. Seems what is becoming more apparent is when we were working on imyc our main contender was 1746 abd as stated that enters everything, hence the huge drain effect when it enters the first cell it contacts afte r systemic delivery. If you could target cells and avoid blood penetration wow? But maybe that is just a dream who knows. I guess cre will tell us that shortly.